Efficacy and Safety of Amphotericin B Emulsion versus Liposomal Formulation in Indian Patients with Visceral L | Sundar, Shyam, Pandey, Krishna, Thakur, Chandreshwar Prasad, Jha, Tara Kant, Das, Vidya Nand Ravi, Verma, Neena, Lal, Chandra Shekhar, Verma, Deepak, Alam, Shahnawaz, Das, Pradeep

Deal Score+2

Read Online Buy Now

Added by

**jake**

on 2014-10-01 18:15:47

SaveSavedRemoved 3

Share on Telegram

⎘

Efficacy and Safety of Amphotericin B Emulsion versus Liposomal Formulation in Indian Patients with Visceral L

User Rating: Be the first one!

Author: Sundar, Shyam, Pandey, Krishna, Thakur, Chandreshwar Prasad, Jha, Tara Kant, Das, Vidya Nand Ravi, Verma, Neena, Lal, Chandra Shekhar, Verma, Deepak, Alam, Shahnawaz, Das, Pradeep

Added by: jake

Added Date: 2014-10-01

Publication Date: 2014-09-18

Language: eng

Collections: pubmed, journals

ISSN Number: 1935-2727 (Print) 1935-2735 (Electronic)

Pages Count: 300

PPI Count: 300

PDF Count: 1

Total Size: 6.83 MB

PDF Size: 877.97 KB

Extensions: djvu, gif, pdf, gz, zip, torrent

Volume: 8

Contributor: Public Library of Science

Archive Url

Downloads: 90

Total Files: 14

Media Type: texts

Read Online Buy Now

Search in PDFforest Search in Telegram

Join Telegram Channel How To Download

Description

This article is from PLoS Neglected Tropical Diseases, volume 8.

Abstract

Background: India is home to 60% of the total global visceral leishmaniasis (VL) population. Use of long-term oral (e.g. miltefosine) and parenteral drugs, considered the mainstay for treatment of VL, is now faced with increased resistance, decreased efficacy, low compliance and safety issues. The authors evaluated the efficacy and safety of an alternate treatment option, i.e. single infusion of preformed amphotericin B (AmB) lipid emulsion (ABLE) in comparison with that of liposomal formulation (LAmB). Methods: In this multicentric, open-label study, 500 patients with VL were randomly assigned in a 3∶1 ratio to receive 15 mg/kg single infusion of either ABLE (N = 376) or LAmB (N = 124). Initial cure (Day 30/45), clinical improvement (Day 30) and long term definitive cure (Day 180) were assessed. Findings: A total of 326 (86.7%) patients in the ABLE group and 122 (98.4%) patients in the LAmB group completed the study. Initial cure was achieved by 95.9% of patients in the ABLE group compared to 100% in the LAmB group (p = 0.028; 95% CI: −0.0663, −0.0150). Clinical improvement was comparable between treatments (ABLE: 98.9% vs. LAmB: 98.4%). Definitive cure was achieved in 85.9% with ABLE compared to 98.4% with LAmB. Infusion-related pyrexia (37.2% vs. 32.3%) and chills (18.4% vs. 18.5%) were comparable between ABLE and LAmB, respectively. Treatment-related serious adverse events were fewer in ABLE (0.3%) compared to LAmB (1.6%). Two deaths occurred in the ABLE group, of which one was probably related to the study drug. Nephrotoxicity and hepatotoxicity was not observed in either group. Conclusions: ABLE 15 mg/kg single infusion had favorable efficacy and was well tolerated. Considering the demographic profile of the population in this region, a single dose treatment offers advantages in terms of compliance, cost and applicability. Trial Registration: www.clinicaltrials.govNCT00876824

Download Zip 1 Pdf 877.97 KB More File Format

Download PDF . 877.97 KB

Efficacy and Safety of Amphotericin B Emulsion versus Liposomal Formulation in Indian Patients with Visceral L | Sundar, Shyam, Pandey, Krishna, Thakur, Chandreshwar Prasad, Jha, Tara Kant, Das, Vidya Nand Ravi, Verma, Neena, Lal, Chandra Shekhar, Verma, Deepak, Alam, Shahnawaz, Das, Pradeep

Efficacy and Safety of Amphotericin B Emulsion versus Liposomal Formulation in Indian Patients with Visceral L

Description

Abstract

Compare items

Shopping cart